Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 2, 2008, Pages 213.e1-213.e7

  Eisenhauer, Eric L ^a   Sonoda, Yukio ^a   Levine, Douglas A ^a   Abu Rustum, Nadeem R ^a   Gemignani, Mary L ^a   Sabbatini, Paul J ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ovarian cancer; primary peritoneal; prognosis; survival

Indexed keywords

PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

EID: 38349129174     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.07.003     Document Type: Article

References (43)

1. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol 77 (1959) 197-200
2. Eltabbakh G.H., and Piver M.S. Extraovarian primary peritoneal carcinoma. Oncology (Williston Park) 12 (1998) 813-819 discussion 20, 25-6
3. Bloss J.D., Liao S.Y., Buller R.E., et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 50 (1993) 347-351
4. Lele S.B., Piver M.S., Matharu J., and Tsukada Y. Peritoneal papillary carcinoma. Gynecol Oncol 31 (1988) 315-320
5. Dalrymple J.C., Bannatyne P., Russell P., et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 64 (1989) 110-115
6. Fromm G.L., Gershenson D.M., and Silva E.G. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 75 (1990) 89-95
7. Ben-Baruch G., Sivan E., Moran O., Rizel S., Menczer J., and Seidman D.S. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 60 (1996) 393-396
8. Bloss J.D., Brady M.F., Liao S.Y., Rocereto T., Partridge E.E., Clarke-Pearson D.L., and Gynecologic Oncology Group Study. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol 89 (2003) 148-154
9. Barda G., Menczer J., Chetrit A., et al., National Israel Ovarian Cancer Group. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 190 (2004) 1039-1045
10. Eltabbakh G.H., Piver M.S., Natarajan N., and Mettlin C.J. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 91 (1998) 254-259
11. Pejovic T., Heim S., Mandahl N., et al. Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 47 (1991) 358-361
12. Mok C.H., Tsao S.W., Knapp R.C., Fishbaugh P.M., and Lau C.C. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 52 (1992) 5119-5122
13. Jacobs I.J., Kohler M.F., Wiseman R.W., et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84 (1992) 1793-1798
14. Li S., Han H., Resnik E., Carcangiu M.L., Schwartz P.E., and Yang-Feng T.L. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 51 (1993) 21-25
15. Tsao S.W., Mok C.H., Knapp R.C., et al. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 48 (1993) 5-10
16. Muto M.G., Welch W.R., Mok S.C., et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 55 (1995) 490-492
17. Schorge J.O., Muto M.G., Welch W.R., et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 90 (1998) 841-845
18. Bandera C.A., Muto M.G., Welch W.R., Berkowitz R.S., and Mok S.C. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 16 (1998) 3455-3459
19. Karlan B.Y., Baldwin R.L., Lopez-Luevanos E., et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 180 (1999) 917-928
20. Levine D.A., Argenta P.A., Yee C.J., et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21 (2003) 4222-4227
21. Beller U., Halle D., Catane R., Kaufman B., Hornreich G., and Levy-Lahad E. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol 67 (1997) 123-126
22. Levy-Lahad E., Catane R., Eisenberg S., et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60 (1997) 1059-1067
23. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283 (2000) 2260-2265
24. Moslehi R., Chu W., Karlan B., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66 (2000) 1259-1272
25. Ben David Y., Chetrit A., Hirsh-Yechezkel G., et al., National Israeli Study of Ovarian Cancer. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20 (2002) 463-466
26. Therasse P., Arbuck S.G., Eisenhauer E.A., et al., European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
27. Rustin G.J., Nelstrop A.E., Tuxen M.K., et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7 (1996) 361-364
28. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
30. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
31. Kennedy A.W., Markman M., Webster K.D., et al. Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. Gynecol Oncol 71 (1998) 288-290
32. Dubernard G., Morice P., Rey A., et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol 30 (2004) 976-981
33. Markman M., Rothman R., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9 (1991) 389-393
34. Markman M., and Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10 (1992) 513-514
35. Killackey M.A., and Davis A.R. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 51 (1993) 171-174
36. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 (2006) 1083-1090
37. Piver M.S., Eltabbakh G.H., Hempling R.E., Recio F.O., and Blumenson L.E. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol 67 (1997) 141-146
38. Eltabbakh G.H., Werness B.A., Piver S., and Blumenson L.E. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol 71 (1998) 230-239
39. Strnad C.M., Grosh W.W., Baxter J., et al. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 111 (1989) 213-217
40. Menczer J., Chetrit A., Barda G., et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 88 (2003) 58-61
41. Rubin S.C., Benjamin I., Behbakht K., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335 (1996) 1413-1416
42. Halperin R., Zehavi S., Langer R., Hadas E., Bukovsky I., and Schneider D. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend?. A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer 11 (2001) 403-408
43. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43